Financial Data and Key Metrics Changes - In Q4 2025, the company reported a revenue of $61.6 million, reflecting a 17% increase compared to Q4 2024 [20] - Full year 2025 revenue growth was 15%, with adjusted EBITDA increasing nearly 75% [6] - The company generated $10 million in free cash flow in Q4 2025, marking its first positive free cash flow quarter in history [6][25] - The gross profit margin improved to 73% in Q4 2025, up from 68% in Q4 2024 [22] Business Line Data and Key Metrics Changes - The Trauma and Deformity (T&D) business grew by 17% in Q4 2025, with global revenue reaching $42.6 million [21] - Scoliosis revenue increased by 13% to $17.6 million in Q4 2025, driven by international implant growth [21] - The Specialty Bracing (OPSB) business continued to support revenue growth and profitability, with strong same-store sales growth [12] Market Data and Key Metrics Changes - U.S. revenue was $48.6 million in Q4 2025, a 13% increase, representing 79% of total revenue [20] - International revenue reached $13.0 million, a 33% increase, accounting for 21% of total revenue [20] Company Strategy and Development Direction - The company aims to help 1 million children annually and is focused on expanding its product portfolio and market presence [7] - A multi-year product innovation cycle is underway, with significant product launches planned, including the 3P Hip and VerteGlide systems [8] - The company is exploring opportunities in other pediatric subspecialties to leverage its commercial footprint [41][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining revenue growth and achieving cash flow breakeven in 2026 [6] - The company anticipates continued share gains and improved EBITDA margins due to new product launches and operational efficiencies [8][33] - Management highlighted the positive surgeon feedback on new products, indicating strong market acceptance [16][75] Other Important Information - The company made structural improvements in Brazil through the acquisition of a distributor, which is expected to enhance cash collection and market penetration [18] - The company is also advancing into the digital health space with the launch of the Playbook platform, aimed at improving surgical efficiency [60] Q&A Session Summary Question: Insights on Scoliosis performance and competitive pressure - Management noted strong growth in the Scoliosis segment, driven by new product launches and increased surgeon adoption [29][30] Question: Outlook on margin progression - Management expects gross margins to remain around 73% in 2026, with adjusted EBITDA projected to increase to $25 million [33] Question: Exploration of options to increase shareholder value - Management indicated interest in expanding the commercial footprint into other pediatric subspecialties, leveraging existing infrastructure [40][41] Question: Updates on 7D placements and strategy - Management reported normal growth in 7D placements, with optimism for 2026 based on strong performance in existing accounts [51] Question: Pricing and margin impact from new product launches - New technologies are expected to command higher premiums, positively impacting profitability over the coming years [82] Question: EU MDR strategy and its impact on OUS market - The approval of a full product range in Europe is anticipated to enhance growth and conversion rates among surgeons [83] Question: Cardiovascular business margin profile - The cardiovascular segment is expected to have a higher gross margin profile compared to the current implant business [85]

Summary of OrthoPediatrics FY Conference Call (December 04, 2025) Company Overview - **Company**: OrthoPediatrics (NasdaqGM: KIDS) - **Industry**: Pediatric orthopedic medical devices Key Points and Arguments Q3 Performance and Guidance Adjustments - Despite a decrease in guidance, the company reported a strong Q3 performance, with challenges primarily in capital sales and Latin America [4][5][6] - The 7D capital product, a navigation platform for spine surgery, had no completed orders in Q3, leading to a significant revenue impact of several million dollars [4][5] - The company has decided to remove 7D revenue from future guidance to provide clearer expectations for investors [6][10] Revenue Growth Components - The company anticipates a baseline growth rate of around 12%, focusing on predictable and high-margin components of the business, including T&D implants and OPSB [32][34] - The scoliosis implant business is expected to remain flat, while international agency sales, particularly in Europe and Australia, are showing strong growth [34] New Product Development - OrthoPediatrics is at the beginning of a new product launch cycle, with significant investments in novel product development expected to impact growth from 2026 onwards [37][38] - Key products include the PNP tibia and femur, which are rapidly growing, and the 3P system, which has received positive feedback and is expected to become a workhorse for the company's hip systems [40][47] Market Opportunities - The plating market is large, with estimates suggesting a collective opportunity exceeding $50 million [48] - The early onset scoliosis (EOS) market in the U.S. is estimated to be over $50 million, with significant potential for growth due to limited competition [88][91] Financial Outlook - The company expects a substantial increase in EBITDA in 2026, with projections indicating a growth rate of around 65% [105][108] - The restructuring efforts and a focus on profitability are expected to positively impact cash flow and operational efficiency [109] Strategic Focus - OrthoPediatrics aims to expand its clinic presence, aspiring to have clinics in every children's hospital in the U.S. and select international markets [104] - The company is focused on generating free cash flow and has limited set deployment to manage cash conversion cycles effectively [58][62] Challenges and Risks - There are theoretical risks associated with not achieving 7D sales, which could impact the spine business, but the company does not anticipate significant negative effects on its implant business [17][29] - The company is cautious about capital deployment for new product launches, ensuring that cash usage aligns with growth strategies [64][68] Additional Important Insights - The company is leveraging advanced technologies in its products, such as RF technology in the LE device, which enhances surgical precision and reduces complications [76][78] - OrthoPediatrics is differentiating itself by focusing on complex surgeries for pediatric patients, which are often overlooked by competitors [71][72] This summary encapsulates the critical insights from the OrthoPediatrics FY Conference Call, highlighting the company's performance, strategic direction, and market opportunities.